secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0000939767-23-000017
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis posts Q4 net loss $30.2M; cabozantinib franchise revenue $1.4B for FY2022
--------------------------------------------------------------------------------

- Q4 total revenues $423.9M, down 6% from $451.1M a year ago; cabozantinib U.S. net product revenues $377.4M.
- GAAP diluted EPS $(0.09) for Q4 vs $0.29 in Q4 2021; full year GAAP diluted EPS $0.56 vs $0.72.
- Non-GAAP diluted EPS $(0.03) for Q4 vs $0.35; full year non-GAAP diluted EPS $0.82 vs $1.01.
- R&D expenses rose to $336.8M in Q4 (from $222.3M) on higher license and collaboration costs.
- Company plans to initiate phase 3 studies of zanzalintinib and advance XB002 into full development in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000017/0000939767-23-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000017/exel-20230207.htm
  HTML page:      https://secwatch.observer/filing/0000939767-23-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer